A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
about
Profile of inhaled glycopyrronium bromide as monotherapy and in fixed-dose combination with indacaterol maleate for the treatment of COPDA randomised, open-label study of umeclidinium versus glycopyrronium in patients with COPDSafety of inhaled glycopyrronium in patients with COPD: a comprehensive analysis of clinical studies and post-marketing data.A case report of QT prolongation with glycopyrronium bromide in a patient with chronic tamoxifen use.Efficacy and safety of once-daily glycopyrronium in predominantly Chinese patients with moderate-to-severe chronic obstructive pulmonary disease: the GLOW7 study.Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled trialProfile of a fixed-dose combination of tiotropium/olodaterol and its potential in the treatment of COPD.Comparative efficacy of long-acting muscarinic antagonist monotherapies in COPD: a systematic review and network meta-analysis.GFF MDI for the improvement of lung function in COPD - A look at the PINNACLE-1 and PINNACLE-2 data and beyond.A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 μg compared with tiotropium 18 μg in patients with COPD.Dual Bronchodilator Therapy with Umeclidinium/Vilanterol Versus Tiotropium plus Indacaterol in Chronic Obstructive Pulmonary Disease: A Randomized Controlled Trial.Efficacy and safety of twice-daily glycopyrrolate in patients with stable, symptomatic COPD with moderate-to-severe airflow limitation: the GEM1 study.Early bronchodilator action of glycopyrronium versus tiotropium in moderate-to-severe COPD patients: a cross-over blinded randomized study (Symptoms and Pulmonary function in the moRnING)Randomized controlled trials and real-world observational studies in evaluating cardiovascular safety of inhaled bronchodilator therapy in COPD.Glycopyrronium bromide for the treatment of chronic obstructive pulmonary disease.Comparative efficacy of long-acting muscarinic antagonists in preventing COPD exacerbations: a network meta-analysis and meta-regression.Strategies for reducing the risk of cardiovascular disease in patients with chronic obstructive pulmonary disease.Long-acting muscarinic antagonists for the prevention of exacerbations of chronic obstructive pulmonary disease.Long-acting muscarinic antagonists.Once-daily glycopyrronium bromide (Seebri Breezhaler(®)) for the treatment of chronic obstructive pulmonary disease (COPD).Summary of the Chronic Obstructive Pulmonary Disease Clinical Practice Guideline Revised in 2014 by the Korean Academy of Tuberculosis and Respiratory Disease.Spotlight on glycopyrronium/formoterol fumarate inhalation aerosol in the management of COPD: design, development, and place in therapy.The lungs need to be deflated: effects of glycopyrronium on lung hyperinflation in COPD patients.Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study.Cost-Effectiveness of Glycopyrronium Bromide Compared with Tiotropium in Patients with Chronic Obstructive Pulmonary Disease in Sweden.Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials.Practical considerations when prescribing a long-acting muscarinic antagonist for patients with COPD.Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.Revised (2018) COPD Clinical Practice Guideline of the Korean Academy of Tuberculosis and Respiratory Disease: A SummaryComparative efficacy of inhaled medications (ICS/LABA, LAMA, LAMA/LABA and SAMA) for COPD: a systematic review and network meta-analysis
P2860
Q26825822-001AF99E-80DD-4895-A879-C74CA7064793Q28596637-79C75087-FAA6-4943-9C38-1DDA5F1FB032Q30990525-04BDC129-0C3B-4450-8ADD-3860E9FAF999Q33167296-67536DDD-56BE-47C1-86FF-2FDA2459F58AQ34944547-D6050BF8-F9DF-4826-829F-333DAF7A5067Q35541687-57B24117-2CDA-48B5-9CF2-552375488E35Q35595077-DCB161F1-2D1C-442D-AFBA-7FF1AA1AEF6DQ35766346-5E6F1274-C045-4ECD-A5D8-AF98F8702FBFQ36307097-DDB693C7-2F2F-4122-86BE-C69D97A520CBQ36356295-BB30D321-3623-40CE-B442-C1337DCBCF4EQ36787818-1B04D0EF-2D68-46BC-9280-A485552AE320Q36924015-D9E77B70-7EB4-408A-9A92-EF154D1DDA6EQ37003186-09B69AAE-B161-4F71-95DF-0E4F3563C5D5Q37069374-48111C48-641F-4B5C-A6A6-4CD0A46C5CE5Q37468663-3991C71D-4DF1-480D-823E-51C7AD478227Q38303157-08961C35-7D3A-4741-A4CD-6A25C252C35DQ38317463-FB7E5ED2-E72F-48A9-979C-53BC2C5AA16BQ38345525-D1DBD655-1E39-4E08-904E-01C9D41A7627Q38388302-21E16DC8-50D8-450B-8BFA-CEFB3317DF9EQ38537326-2E782D25-827E-45D4-A5B1-53CEB4142CEBQ38660895-31F43890-98C1-4613-81D8-1DBEC9F66DCDQ40106829-2C62F92A-28E2-44B2-AE5A-BFB78455037EQ41282858-5E8EB794-5843-427F-A9A0-E0737252F454Q41908094-7482AD96-7609-43D3-B693-820D6A1F53ABQ47122143-10A91E98-BA6F-4C14-AFF6-A48BE809B9CFQ51287554-0AA81767-B5FD-4E74-945A-24A0604A16C0Q54962114-D119F13D-B06D-4103-955A-025344D41B21Q55120067-5F272197-96A4-410D-B5C7-031D2374B38AQ55387524-29D68DB5-7B59-4040-926E-364D32081995Q57210495-D219F7EE-8529-4B79-B29E-213E8F920D8DQ57817177-C61266E2-8618-416C-8428-CC97464B7229
P2860
A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A blinded evaluation of the ef ...... nts with COPD: the GLOW5 study
@en
A blinded evaluation of the ef ...... ts with COPD: the GLOW5 study.
@nl
type
label
A blinded evaluation of the ef ...... nts with COPD: the GLOW5 study
@en
A blinded evaluation of the ef ...... ts with COPD: the GLOW5 study.
@nl
prefLabel
A blinded evaluation of the ef ...... nts with COPD: the GLOW5 study
@en
A blinded evaluation of the ef ...... ts with COPD: the GLOW5 study.
@nl
P2093
P2860
P356
P1476
A blinded evaluation of the ef ...... nts with COPD: the GLOW5 study
@en
P2093
Anthony D'Urzo
Eric D Bateman
Hungta Chen
Jutta Beier
Kai-Michael Beeh
Michelle Henley
Peter D'Andrea
Robert Nutbrown
Tim Overend
P2860
P2888
P356
10.1186/1471-2466-14-4
P577
2014-01-17T00:00:00Z
P5875
P6179
1047049653